Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387130385> ?p ?o ?g. }
- W4387130385 endingPage "2624" @default.
- W4387130385 startingPage "2615" @default.
- W4387130385 abstract "Fibrodysplasia ossificans progressiva (FOP) is a rare disease characterized by heterotopic ossification (HO) in connective tissues and painful flare-ups. In the phase 2 LUMINA-1 trial, adult patients with FOP were randomized to garetosmab, an activin A-blocking antibody (n = 20) or placebo (n = 24) in period 1 (28 weeks), followed by an open-label period 2 (28 weeks; n = 43). The primary end points were safety and for period 1, the activity and size of HO lesions. All patients experienced at least one treatment-emergent adverse event during period 1, notably epistaxis, madarosis and skin abscesses. Five deaths (5 of 44; 11.4%) occurred in the open-label period and, while considered unlikely to be related, causality cannot be ruled out. The primary efficacy end point in period 1 (total lesion activity by PET-CT) was not met (P = 0.0741). As the development of new HO lesions was suppressed in period 1, the primary efficacy end point in period 2 was prospectively changed to the number of new HO lesions versus period 1. No placebo patients crossing over to garetosmab developed new HO lesions (0% in period 2 versus 40.9% in period 1; P = 0.0027). Further investigation of garetosmab in FOP is ongoing. ClinicalTrials.gov identifier NCT03188666 ." @default.
- W4387130385 created "2023-09-29" @default.
- W4387130385 creator A5000903477 @default.
- W4387130385 creator A5002782925 @default.
- W4387130385 creator A5005235245 @default.
- W4387130385 creator A5012384299 @default.
- W4387130385 creator A5015097681 @default.
- W4387130385 creator A5016868644 @default.
- W4387130385 creator A5017875593 @default.
- W4387130385 creator A5017933909 @default.
- W4387130385 creator A5021852790 @default.
- W4387130385 creator A5022037416 @default.
- W4387130385 creator A5022155056 @default.
- W4387130385 creator A5022722734 @default.
- W4387130385 creator A5025590744 @default.
- W4387130385 creator A5027169785 @default.
- W4387130385 creator A5032369391 @default.
- W4387130385 creator A5032992841 @default.
- W4387130385 creator A5038455658 @default.
- W4387130385 creator A5039132988 @default.
- W4387130385 creator A5040685027 @default.
- W4387130385 creator A5040724385 @default.
- W4387130385 creator A5042703700 @default.
- W4387130385 creator A5048640756 @default.
- W4387130385 creator A5048919835 @default.
- W4387130385 creator A5054286661 @default.
- W4387130385 creator A5055944239 @default.
- W4387130385 creator A5056285244 @default.
- W4387130385 creator A5057391125 @default.
- W4387130385 creator A5057773843 @default.
- W4387130385 creator A5060111768 @default.
- W4387130385 creator A5060656642 @default.
- W4387130385 creator A5067664293 @default.
- W4387130385 creator A5071149552 @default.
- W4387130385 creator A5071375873 @default.
- W4387130385 creator A5074062985 @default.
- W4387130385 creator A5085084466 @default.
- W4387130385 creator A5085672493 @default.
- W4387130385 date "2023-09-28" @default.
- W4387130385 modified "2023-10-18" @default.
- W4387130385 title "Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial" @default.
- W4387130385 cites W180266173 @default.
- W4387130385 cites W2035749891 @default.
- W4387130385 cites W2042437927 @default.
- W4387130385 cites W2066050937 @default.
- W4387130385 cites W2070755192 @default.
- W4387130385 cites W2072958717 @default.
- W4387130385 cites W2101401558 @default.
- W4387130385 cites W2105521580 @default.
- W4387130385 cites W2120126656 @default.
- W4387130385 cites W2134813590 @default.
- W4387130385 cites W2145304853 @default.
- W4387130385 cites W2154767933 @default.
- W4387130385 cites W2158110141 @default.
- W4387130385 cites W2165275292 @default.
- W4387130385 cites W2169474931 @default.
- W4387130385 cites W2187451625 @default.
- W4387130385 cites W2233753612 @default.
- W4387130385 cites W2344770548 @default.
- W4387130385 cites W2609070098 @default.
- W4387130385 cites W2625396153 @default.
- W4387130385 cites W2727903747 @default.
- W4387130385 cites W2743394875 @default.
- W4387130385 cites W2758460251 @default.
- W4387130385 cites W2786308339 @default.
- W4387130385 cites W2895220437 @default.
- W4387130385 cites W2921438290 @default.
- W4387130385 cites W2947119195 @default.
- W4387130385 cites W3000098586 @default.
- W4387130385 cites W3036026816 @default.
- W4387130385 cites W3092937180 @default.
- W4387130385 cites W3110199885 @default.
- W4387130385 cites W3120336759 @default.
- W4387130385 cites W3189980870 @default.
- W4387130385 doi "https://doi.org/10.1038/s41591-023-02561-8" @default.
- W4387130385 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37770652" @default.
- W4387130385 hasPublicationYear "2023" @default.
- W4387130385 type Work @default.
- W4387130385 citedByCount "0" @default.
- W4387130385 crossrefType "journal-article" @default.
- W4387130385 hasAuthorship W4387130385A5000903477 @default.
- W4387130385 hasAuthorship W4387130385A5002782925 @default.
- W4387130385 hasAuthorship W4387130385A5005235245 @default.
- W4387130385 hasAuthorship W4387130385A5012384299 @default.
- W4387130385 hasAuthorship W4387130385A5015097681 @default.
- W4387130385 hasAuthorship W4387130385A5016868644 @default.
- W4387130385 hasAuthorship W4387130385A5017875593 @default.
- W4387130385 hasAuthorship W4387130385A5017933909 @default.
- W4387130385 hasAuthorship W4387130385A5021852790 @default.
- W4387130385 hasAuthorship W4387130385A5022037416 @default.
- W4387130385 hasAuthorship W4387130385A5022155056 @default.
- W4387130385 hasAuthorship W4387130385A5022722734 @default.
- W4387130385 hasAuthorship W4387130385A5025590744 @default.
- W4387130385 hasAuthorship W4387130385A5027169785 @default.
- W4387130385 hasAuthorship W4387130385A5032369391 @default.
- W4387130385 hasAuthorship W4387130385A5032992841 @default.
- W4387130385 hasAuthorship W4387130385A5038455658 @default.
- W4387130385 hasAuthorship W4387130385A5039132988 @default.